Lawrence Klein - Sep 10, 2021 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
CBO & COO
Signature
/s/ Michael Esposito, attorney-in-fact
Stock symbol
CRSP
Transactions as of
Sep 10, 2021
Transactions value $
-$495,837
Form type
4
Date filed
9/14/2021, 09:44 PM
Previous filing
May 27, 2021
Next filing
Oct 1, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise +10K +952.38% 11.1K Sep 10, 2021 Direct F1, F2
transaction CRSP Common Shares Tax liability -$496K -4.21K -38.07% $117.86 6.84K Sep 13, 2021 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Tax liability -10K -100% 0 Sep 10, 2021 Common Shares 10K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock unit award was granted on September 10, 2019 with respect to 10,000 Common Shares, with all shares vesting on September 10, 2021.
F2 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F3 Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.